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AbstrACt
Introduction Infection with the Cryptosporidium 
parasite causes over 4000 cases of diagnosed illness 
(cryptosporidiosis) in England and Wales each year. Risk 
factors are often estimated from outbreak investigations, 
and in the UK include ingestion of contaminated water and 
food, farm/animal contact and person-to-person spread in 
institutions. However, reported outbreaks only represent 
about 10% of cases and the transmission routes for sporadic 
disease may not be the same. Contact with other people 
has been highlighted as a factor in the transmission of 
Cryptosporidium, but the incidence of sporadic disease 
has not been sufficiently established, and how frequently 
this arises from contact with other infected people is not 
well documented. This project will estimate the amount of 
secondary spread that occurs in the home and potentially 
identify asymptomatic infections which might have a role in 
transmission. Risk factors and characteristics associated with 
secondary spread will be described including any differences 
in transmission between Cryptosporidium species.
Methods and analysis The study will prospectively identify 
cryptosporidiosis cases from North West England and Wales 
over 1 year and invite them and their household to take part. 
Each household will complete a questionnaire and each 
household member will be asked to provide a stool sample. 
Clinical, demographic and home variables will be described, 
and further analyses undertaken to investigate associations 
with secondary spread in the home. Cryptosporidium-
positive stool samples, identified by immunofluorescence 
microscopy, will be characterised using molecular methods 
to describe patterns of transmission. Data collection is 
expected to take 1 year, beginning in September 2018.
Ethics and dissemination The study has been approved 
by the North West–Liverpool East NHS Research 
Ethics Committee (Reference: 18/NW/0300) and the 
Confidentiality and Advisory Group (Reference 18/
CAG/0084). Outputs will include scientific conferences and 
peer-reviewed publications. In addition, a short, lay report 
of findings will be produced for participants, who can opt 
to receive this when they take part. 
trial registration number CPMS ID: 39458.
IntroduCtIon
Cryptosporidium is a protozoan parasite which 
can infect humans and other animals, and 
the most prevalent species identified in 
humans are Cryptosporidium parvum and 
Cryptosporidium hominis.1 2 Cryptosporid-
iosis is the subsequent diarrhoeal disease 
following infection with Cryptosporidium. The 
disease affects all ages and although gener-
ally self-limiting, can be life threatening in 
some immune-compromised patients. Acute 
diarrhoea follows an incubation period of 
between 2 and 10 days (mean 7 days) and 
symptoms can include non-bloody diarrhoea, 
abdominal cramps, vomiting and/or nausea, 
low grade fever, lethargy and general malaise.
Public Health England (PHE) receive labo-
ratory reports of over 4000 diagnosed cases 
per year (2000–2012 data) in England and 
Wales; however, research indicates that many 
infections may go undiagnosed, and the true 
incidence of disease may be much greater.3 4
The parasite has a complex life cycle and 
characteristics which favour faecal-oral and 
environmental transmission routes, which 
may facilitate outbreaks via person-to-person 
(C. hominis and C. parvum) or animal-to-person 
strengths and limitations of this study
 ► This prospective household study will provide de-
tailed information on the incidence of, and risk fac-
tors for, secondary spread of cryptosporidiosis in the 
home.
 ► This study will characterise Cryptosporidium iso-
lates to ascertain likely mechanisms of spread by 
species.
 ► This study will potentially identify the prevalence of 
asymptomatic infections with Cryptosporidium.
 ► Common exposures across households may present 
problems with accurately identifying true secondary 
spread.
 ► Biases may lead to a skewed sample of index cas-
es because of under-ascertainment and bias in 
health-seeking behaviours.
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(C. parvum) contact, as well as indirect transmission 
through ingestion of water and food contaminated with 
infectious oocysts.5
Risk factors and associated exposures are often 
hypothesised/identified from outbreak investigations, 
however recognised outbreaks may only represent a 
small proportion of cases; estimates in the UK suggest, 
of all cases reported to national surveillance, <10% are 
likely to be linked to an identified outbreak6 and 
contact with other people is highlighted as a factor in 
the transmission of Cryptosporidium. In a 1988 paper, 
onward transmission of Cryptosporidium was reported 
in households in the UK following a nursery outbreak, 
probably propagated by person-to-person spread in the 
home.7 An analysis of outbreak reports from surveil-
lance data in Ireland reported that ingestion of water 
and person-to-person spread were the most important 
mechanisms of transmission in outbreaks.8 In the USA, 
in a case–control study evaluating sporadic cryptospo-
ridiosis among immunocompetent persons, risk factors 
associated with increased odds of being a case were 
international travel, contact with cattle and contact with 
a child with diarrhoea.9 In 2001–2002, a case–control 
study conducted in the North West of England exam-
ined species-specific risk factors for sporadic crypto-
sporidiosis.10 The authors compared risk factors for 
infection with genotypes 1 and 2 (currently recognised 
as C. hominis and C. parvum, respectively) and found 
that contact with another person with diarrhoea was a 
risk factor for infection with Cryptosporidium, and that 
changing children’s nappies was a specific risk factor 
for infection with C. hominis whether the child was symp-
tomatic or not symptomatic. Studies of Giardia, another 
gastrointestinal parasite, similar in terms of likely trans-
mission routes, have recently been undertaken in the 
UK, and secondary spread and person-to-person trans-
mission seems a likely and under-recognised route of 
transmission.11 12 In a 1988 paper, onward transmission 
of Cryptosporidium was reported in households in the 
UK following a nursery outbreak, probably propagated 
by person-to-person spread in the home.9 An analysis 
of outbreak reports from surveillance data in Ireland 
reported that ingestion of water and person-to-person 
spread were the most important mechanisms of trans-
mission.10 In the USA, a study evaluated sporadic cryp-
tosporidiosis among immunocompetent persons using 
a case–control design. Risk factors associated with 
increased odds of being a case were international travel, 
contact with cattle and contact with a child with diar-
rhoea. In 2001–2002, a case–control study conducted 
in the North West of England examined species-specific 
risk factors for sporadic cryptosporidiosis. The authors 
compared risk factors for infection with genotypes 1 
and 2 (currently recognised as C. hominis and C. parvum, 
respectively) and found that contact with another 
person with diarrhoea was a risk factor for infection with 
Cryptosporidium, and that exposure through changing 
children’s nappies was a specific risk factor for infection 
with C. hominis whether the child was symptomatic or 
not symptomatic.
Asymptomatic spread
The burden of asymptomatic infection is less well docu-
mented in Cryptosporidium research than for other infec-
tions but may be an important factor in household 
spread. A study in the UK reported a point prevalence of 
1.3% among asymptomatic pre-school children attending 
daycare13 suggesting that asymptomatic infection does 
occur. A Norwegian study looking at follow-on spread 
after two outbreaks found both asymptomatic and symp-
tomatic infections in the households, which were likely to 
have been a result of secondary transmission.14 Overall 
though, most of the work examining household spread 
has been undertaken in Cryptosporidium-endemic coun-
tries, where a high prevalence and repeated exposure 
to the organism might facilitate transmission, although 
immunity following repeat exposure is still poorly under-
stood.15 16 Newman et al undertook a prospective cohort 
study in Brazil to examine the transmission of Cryptospo-
ridium infection in households where there was an identi-
fied case.17 Secondary cases of infection occurred in 58% 
of households, and around a quarter of the identified 
secondary cases had diarrhoea, indicating the presence 
of asymptomatic infection in almost three-quarters of the 
participants. Similar results were reported from a longitu-
dinal study in Bangladesh, where asymptomatic infection 
was more prevalent than diarrhoeal disease.18 The same 
authors followed up with a case–control study in which 
the secondary attack rate was over 35%, and evidence 
of transmission in the home was further supported by 
genotyping results.19 If person-to-person spread is driven 
by both cases and those with asymptomatic infections of 
Cryptosporidium, then sporadic cases may subsequently 
arise following exposure to either, and outbreaks in close 
settings such as the home or institutions may happen 
more frequently than is currently recognised. Few studies 
exist which refute or confirm this, especially in industri-
alised countries.
AIMs And objECtIvEs
The aim of this study is to estimate the amount of onward 
spread of Cryptosporidium that happens in the home, 
and to describe associated factors and case characteris-
tics. (We use the term ‘secondary spread’ to mean any 
apparent onward transmission of disease originating 
from a case, while recognising that this may be secondary 
or even tertiary levels of spread.) This study will support 
our understanding of continued apparent sporadic cryp-
tosporidiosis in England and Wales and has implications 
for appropriate public health messages to help mitigate 
spread and infection. Further molecular characterisation 
of Cryptosporidium isolates may also help define the likeli-
hood of secondary transmission by infecting species.
objectives
 ► To estimate the number of secondary cases in house-
holds with an index case.
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 ► To calculate the secondary transmission rate in 
households.
 ► To estimate the prevalence of asymptomatic carriage 
in households with an index case.
 ► To identify specific household-level and personal 
characteristics associated with secondary spread.
 ► To determine if factors and characteristics asso-
ciated with secondary spread vary by species of 
Cryptosporidium.
MEthods
study population
The study population will comprise residents of North 
West England and Wales.
The North West of England has a population of over 
seven million people and is the third-most populated 
region in the UK.20 In 2016, over 600 laboratory-con-
firmed Cryptosporidium isolates were reported from the 
North West (8.4/100 000 population).21
Wales has a total population of over three million 
people.22 In 2016, over 400 laboratory-confirmed Crypto-
sporidium isolates were reported from Wales, the highest 
rate of Cryptosporidium spp laboratory reports per 100 000 
population in England and Wales (15/100 000).21
surveillance/sampling frame
The sampling frame will be taken from the two relevant 
surveillance systems which capture laboratory confirmed 
reports of Cryptosporidium: The Second-Generation Surveil-
lance System in PHE, and Tarian in Public Health Wales 
(PHW). Systematic national surveillance of laboratory 
confirmed Cryptosporidium in England and Wales has been 
established for many years.23 In the UK, Cryptosporidium is a 
notifiable causative agent, meaning laboratories have a stat-
utory duty to notify the relevant public health authority of its 
identification in any human samples.24 25 Cryptosporidiosis 
may present similarly to other causes of gastroenteritis, and 
laboratory confirmation of infection with Cryptosporidium 
is necessary for a diagnosis. Clinical practice may differ, 
and clinicians would likely submit a sample to a primary 
diagnostic microbiology for a diagnosis of gastroenteritis. 
Local diagnostic laboratories across the UK use different 
methods to test for Cryptosporidium, and various criteria 
to decide whether to test for this parasite, including stool 
consistency, history or clinical details, duration of hospital-
isation or clinician requests.26 Positive samples identified 
in the diagnostic laboratories are routinely forwarded to 
the national Cryptosporidium reference unit (CRU) which 
provides expert management, prevention and control 
advice as well as Cryptosporidium typing and confirmation 
services for speciation and surveillance.27
All cases of laboratory confirmed Cryptosporidium sp. 
reported from primary diagnostic microbiology laborato-
ries in North West England and Wales, in the study year, 
will initially be eligible.
study type
The identification of cases, and their subsequent recruit-
ment, is cross-sectional, although the study also involves 
retrospective data collection and some prospective 
sampling (figure 1).
Cases of cryptosporidiosis will be identified via the 
relevant surveillance system(s). Once participants are 
recruited, they will complete a questionnaire (one per 
household), collecting clinical (onset date, symptoms of 
any household member, other illnesses of index case), 
demographic (age, sex, relationship to the index case) 
and household composition (type, number of bath-
rooms and bedrooms, animals) information. In addition, 
consenting household members (excluding the index 
case) will be asked to supply a stool sample.
study period
The study period will be 12 months, to account for 
seasonal variation and allow maximum enrolment, up to 
400 households. The study is expected to begin with a 
pilot phase of 1–2 months in autumn 2018.
sample size
Given that the North West & Wales report around 1000 
cases per year (PHE data, 2015) and assuming a partic-
ipation rate of 40%–60%, and some exclusions (based 
on similar studies/approaches11 28) we anticipate a 
sample size of 400 households. Using 2011 Census indi-
cations of 2.4 persons on average per household,20 we 
can expect to recruit around 960–1000 participants in 
total. Assuming that the rate of household transmission, 
defined as the proportion of households with more than 
one case, is between 0% and 20%,11 14 17 29–31 a range of 
sample sizes was estimated (118–402). Recruitment of 
400 households is feasible and is sufficient to allow us 
to demonstrate a statistically significant minimum odds/
risk ratio of 2.0, with type 1 error 0.05 and type 2 error 
at 0.20.
Case definition(s)
Boxes 1 and 2 outline case and household definitions used 
to categorise household members and define secondary 
transmission.
Figure 1 Outline of study.
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recruitment approach
Overview and rationale
Cases of cryptosporidiosis are identified from routine 
surveillance (from diagnostic laboratories) and are 
contacted via post, by the relevant public health organi-
sation, in the first instance. Following this, if they do not 
opt-out, they are contacted via telephone by a National 
Health Service (NHS) research nurse at the local Clin-
ical Research Network (CRN) to chat about the study and 
determine if they would like to take part.
Our approach to the recruitment process was driven by 
necessity and feasibility and we explored several options 
at the protocol drafting stage of the project, balancing 
data needs with patient choice. As our capture of cases 
in the surveillance systems is retrospective and diagnosis 
of Cryptosporidium in the stool sample is undertaken by 
laboratory staff, there is no opportunity to consent indi-
viduals at the time of diagnosis and the recruitment 
process could not be achieved without access to patient 
information. In our model, participants are given opt-out 
options at each contact and it is emphasised that they 
can withdraw at any time. Previous research supports 
the acceptability and understanding of this method, 
recognising that an approach of ‘consent for each use’ 
is burdensome for both researcher and participant,32 33 
as does patient response and engagement with similar 
studies. (Studies recruiting based on disease surveillance 
are common for GI infections, and many projects have 
taken this approach – the methodology for the epiCrypt 
Study has been influenced by design aspects of large-scale 
studies such as Enigma, IID2 and Integrate.)
Public and patient involvement
Patients and public were not involved in the overall 
design of the study, but we did elicit some public opinion 
when finalising our approach to recruitment. Following 
valuable comments from the ethical review board we 
undertook a short survey among the public and specific 
Patient and public involvement (PPI) groups to gauge 
general attitudes toward accessing data prior to consent, 
to support recruitment to research. We drafted a survey 
which outlined the approach to recruitment and the 
framework of the study. We accessed a lay PPI group from 
the Infection and Global Heath panel at the University 
of Liverpool, and one from Health and Care Research 
Wales. Participants were asked to think generally about 
the method of recruitment and how they felt about this 
approach. In general, the feeling was that it is acceptable 
to access data for recruitment, especially to support much 
needed research. However, considerations and worries 
included the person accessing data, with NHS/public 
health staff generally viewed as more favourable that 
non-NHS (eg, university) researchers.
box 1 Case definitions
Index caseIndex case
The first case from a household identified in the surveillance system 
(person reported to a Public Health England/Public Health Wales surveil-
lance system(s) following detection of Cryptosporidium sp. in a faecal 
sample, with a specimen date in the study year).The first case from 
a household identified in the surveillance system (person reported to 
a Public Health England/Public Health Wales surveillance system(s) 
following detection of Cryptosporidium sp. in a faecal sample, with a 
specimen date in the study year).
household casehousehold case
Any household member of a index case who reports symptoms con-
sistent with Cryptosporidium (diarrhoea and/or vomiting) and/or has 
a Cryptosporidium positive stool sample.Any household member of a 
index case who reports symptoms consistent with Cryptosporidium (di-
arrhoea and/or vomiting) and/or has a Cryptosporidium positive stool 
sample.
secondary case(s)*secondary case(s)*
Probable secondary case
A person in a household of an index case, with symptoms:
of diarrhoea and/or vomiting
AND
that started after another case’s onset date in the household.
Confirmed secondary case
A person in a household of an index case, with symptoms:
of diarrhoea and/or vomiting
AND
that started after another case’s onset date in the household
AND
a Cryptosporidium positive stool sample.
AsymptomaticAsymptomatic
A person in a household of an index case with:
no reports of gastrointestinal illness
AND
a Cryptosporidium positive stool sample.
*We use the term ‘secondary spread’ to mean any apparent onward 
transmission of disease originating from an index case, while recognising that 
this may be secondary or even tertiary levels of spread.
box 2 household definition
householdhousehold
Two or more people (not necessarily related) living at the same address 
in North West England or Wales who share cooking facilities and share 
a living room or sitting room or dining area.18Two or more people (not 
necessarily related) living at the same address in North West England 
or Wales who share cooking facilities and share a living room or sitting 
room or dining area.18
household memberhousehold member
A person who normally resides in the household and regularly shares 
food or toilet facilities.38A person who normally resides in the household 
and regularly shares food or toilet facilities.38
household contacthousehold contact
A household member where an index case has been identified.A house-
hold member where an index case has been identified.
household with transmissionhousehold with transmission
A household that has more than one case.A household that has more 
than one case.
household without transmissionhousehold without transmission
A household that has one case (the index case).A household that has 
one case (the index case).
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Identification and first contact with the index case
Laboratory diagnosed reports of Cryptosporidium, and the 
corresponding patient contact details, will be extracted 
from the relevant surveillance system by health protection 
staff and saved in a line list (the Master copy of a confi-
dential, separate table (MS Excel spreadsheet) holding 
patient details of all downloaded cases).
All potentially eligible participants will be issued a 
unique sequential study ID by PHE/PHW staff. This will 
be on all relevant study documentation and stool pots 
and follow each person and household through the study 
journey. This will allow data to be linked pseudonymously 
and helps with data management.
Staff from either PHE or PHW (depending on case loca-
tion) will send an invite letter through the post to these 
potentially eligible index cases. The invite letter outlines 
the study, describes why the case has been contacted and 
explains that a research nurse may be in touch over the 
coming weeks to discuss the study. The letter allows the 
case to choose several ways of opting-out of this contact 
(email, freepost, telephone) and provides a named, clin-
ical study lead for each public health organisation should 
they wish to discuss any aspect of this.
Approaching to recruit
If a contacted index case does not opt-out within 2 weeks, 
their details will be shared securely (using internally 
agreed practices) with the NHS research nurses at the 
CRN North West Coast. The research nurses will attempt 
to contact the index case (or parent/guardian of) via 
telephone (using internally agreed practices) to inform 
them about the study and offer them the opportunity to 
participate, if eligible. A maximum of three attempts will 
be made, and nurses will not leave voicemails. If a case is 
unable to be contacted, or does not wish to participate at 
this stage, their details will be deleted from the line list. 
If the approached index case is successfully contacted via 
telephone and interested in participating, or would like 
more information, the research nurses will prepare and 
post a study pack. Index cases may be excluded at this 
stage where discussions with the case reveal that any of 
the following exclusion criteria apply:
 ► Index case is in a single-person household.
 ► Index case is a visitor to a household in the study area, 
but is registered with a general practice (GP) outside 
the study area.
 ► Household is outside the study area.
 ► The index case is resident in an institution: retire-
ment home, nursing home, prison, barracks, 
boarding school or college/university halls of 
residence.
study packs
The study packs contain:
 ► A study information pamphlet.
 ► A questionnaire booklet for the index case or a suit-
able representative (eg, parent, head of household) 
to complete, with a freepost envelope.
 ► A consent form for each participating household 
member to read, initial and sign (forms part of the 
questionnaire)).
 ► A stool sampling pack (Fe-Col) for each participating 
household member, with the required return postal 
envelope.
 ► An information leaflet on cryptosporidiosis and the 
relevant health advice.
 ► An information sheet on General Data Protection 
Regulation for health and care research.
Consent
The index case and any household members who wish 
to take part will sign and return the consent form at the 
front of the questionnaire. The return of study materials 
such as a completed questionnaire and/or stool samples 
will be considered implied consent.
disenrollment 
If study materials are not received within 14 days of 
posting the pack, a reminder letter will be dispatched by 
the research nurses at the CRN. If study documentation 
is not returned within 14 days of posting the reminder 
letter, no further attempt at contact will be made, and the 
index case will be removed from the study line list.
Participation
If the household wants to take part, all interested members 
will sign and return the consent form. At least one house-
hold member, as well as the index case, must consent.
Consent forms and questionnaires are returned to the 
University of Liverpool in a stamped addressed envelope 
provided in the pack. The unique study IDs of those 
consenting will be shared weekly with the research nurses 
at the CRN to cross-match those contacted index cases 
that have been recruited and enrolled. Each consenting 
household member will also be asked to provide a stool 
sample for testing, using the provided Fe-Col kits, which 
include a pre-addressed and secure postal bag (compliant 
with UN3373 regulations for mailing Cat B biological 
samples34). Instructions are provided, and samples will be 
returned directly to the CRU.
data management and oversight
Documentation
Questionnaire data will be inputted from the paper 
format to a corresponding MS Access database and held 
securely on a University of Liverpool drive in accordance 
with their security protocols. Figure 2 shows the data flow 
expected. Double data entry will be undertaken on a 
sample of questionnaires and discrepancies resolved using 
internal validation checks. When data entry is complete 
the data will be exported to the final study database (MS 
Access) where the data are pseudonymised for analyses: 
Name, date of birth and full postcode will be removed 
and replaced with unique study ID, age and Lower Super 
Output Area (a type of geographic area in England and 
Wales, comprised >1000 residents35).
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All data storage, cleaning and analyses will be under-
taken by the study team at the University of Liverpool. 
Data will be stored on institutional network drives with 
appropriate security measures in place. Hard copy 
records will be stored in a locked cabinet in a secure loca-
tion and access to records and data are limited to study 
personnel. Paper documents will be stored separately 
from the corresponding electronic data. The sponsor and 
data controller for this study is the Clinical Governance 
Team at the University of Liverpool.
data security protocol available on request
Stool sample management
For purposes of data confidentiality and governance, 
stool samples returned to the CRU are pseudonymised 
with the unique study ID, and participants will be asked 
to write their age, sex and date of sample on their sample 
pot before they collect the stool. Stool sample results will 
be added to a study-specific database held at the CRU. 
The stool sample results will be added to the study data-
base at the end of data collection using unique study ID 
in a secure file transfer.
Identifying the index case samples
Original diagnostic laboratory numbers will be retained 
with the index case information in the original line lists 
at PHE/PHW so that the sample can be identified later 
at the CRU and grouped with the relevant household 
samples. This sample, when located at the CRU, will be 
processed in the same way as other study samples.
Full laboratory protocol available on request
Outcomes and measurements
Questionnaire data
The questionnaire is divided into sections and is mostly 
composed of dichotomous and multiple-choice questions. 
Section A asks questions to determine the composition of 
the household, the clinical details of the index case, and 
captures any other symptomatic household members. A 
table is used to collect information on any other symp-
tomatic diarrhoeal illness in the house and will attempt to 
capture relationships to the index case (table 1).
Section B records activities of the index case, and others 
in the home, in the 2 weeks prior to the index case’s onset, 
based on known exposures for Cryptosporidium. Informa-
tion on outdoor and leisure activities may help determine 
possible co-primary infections and distinguish them from 
those that are secondary (table 2).
Sections C and D collect household variables, including 
the number of bedrooms and bathrooms, and capturing 
those who share beds/baths, and asking about outside 
space and animals. We also ask about nappy changing 
and toilet training in the home, and about general hand-
washing behaviour.
Table 1 An example table showing information collected in the questionnaire about other illness in the house
Age Sex
Relationship to first 
case
Been ill with diarrhoea 
and/or vomiting
(Yes/No/Don’t know)
When they became ill
(Date if known, otherwise 
before/after the first 
case)
How many days 
were they ill with 
these symptoms?
Did they see a 
doctor about this 
illness?
39 F Mother Yes 18/12/2017 10 No
42 M Father Yes Before About 3 days No
6 months M Brother No –
24 F Lodger/housemate Don’t know – 
Table 2 An example table showing information collected in 
the questionnaire about activities
Activity
First 
case
Anyone else in 
the home
Travel outside the UK
Swimming—outdoors in a lake, river, 
stream, etc (wild swimming)
Swimming—in a treated swimming pool, 
either indoors or outdoors (such as a 
pool at a leisure centre or a lido)
Other water activities/sport (such as 
surfing, rowing, water-skiing, etc)
Other outdoor activities (such as 
camping, climbing, hiking, cycling, etc)
Gardening (at home or elsewhere, such 
as an allotment)
Contact with pets (at home or with pets 
at another house)
Visiting or working on a farm or had 
contact with farm animals
Visiting or working at a zoo or had 
contact with zoo or wild animals
Figure 2 Study flow diagram.
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Full questionnaire available on request
Stool collection and genotyping
All consenting household members of the index case (but 
not the index case) will be asked to provide a stool sample 
using the Fe-Col kit (figure 3) provided in the study pack, 
and post to the CRU.
The stool pots will be labelled with the unique house-
hold ID which identifies them as part of the study but 
allows the samples to remain anonymous to the refer-
ence laboratory team. Samples will be scored against the 
Bristol stool scale and tested and quantified, only for Cryp-
tosporidium, using immunofluorescence microscopy and 
real-time PCR. Positive samples will be speciated using 
validated PCR techniques which are part of normal prac-
tice.36 Cryptosporidium DNA will be retained for subtyping 
and possibly whole genome sequencing at a later date.
Full laboratory protocol available on request
Analyses
The primary objective of this study is to determine the 
amount of spread that happens in the home where there 
is a case of Cryptosporidium. This will be established by 
testing stool samples of household members of a case 
for Cryptosporidium and reporting the numbers of other 
cases (according to our predetermined definitions in 
box 1). A household with more than one case of any 
type will be a household with transmission. As we are 
only able to capture cases of Cryptosporidium using labora-
tory confirmed cases reported to surveillance, we recog-
nise that what we may define as an ‘index’ case, may not 
be, in true epidemiological terms, the first case that has 
driven transmission. While it is important that cases are 
identified and recruited based on the same diagnostic 
criteria, we accept that the identification of index cases is 
a pre-enrolment definition. Following enrolment of the 
household into the study, and the return of documenta-
tion, an index case may be categorised differently, and 
may actually fit the definition for a secondary case. This 
will be analysed at the household level and depends on 
the accurate population of fields in the questionnaire. 
In doing this, we are able to more accurately describe 
transmission in the home, and this may well allow us to 
describe the characteristics of these true index cases, and 
why we do not pick them up in surveillance, for example, 
if they exhibit different health-seeking behaviour.
We will calculate the following:
 ► The secondary transmission rate/prevalence within 
households (number of cases in the home/numbers 
at risk in the home, number of households with 
secondary spread/number of households)).
 ► The amount of asymptomatic carriage among those 
exposed to symptomatic cases (number of asympto-
matic cases/number at risk)).
 ► OR/RR of secondary illness according to activities 
and case/household characteristics;
 ► OR/RR of secondary illness according to organism 
species.
Confounding (eg, host factors such as age, comor-
bidity) will be considered, where known, using multivar-
iable techniques. Also, we will, where possible, examine 
environmental level exposures using stratification, for 
example, those households/cases which are exposed to 
other known sources or risk factors, such as those living 
on farms.
Data will be analysed using Stata V.12.
Limitations and biases
Some elements of the study design are retrospective in 
nature, as the index case must have already been ill and 
been tested in order to be selected. As a result, some ascer-
tainment bias may lead to a skewed sample from which to 
choose the index cases. We do not expect to capture the 
full profile of cases and households in the population that 
might have Cryptosporidium due to differences in risk or 
vulnerability, severity or health-seeking behaviour.37 We 
may get an over-representation of severe disease as these 
cases are more likely to seek healthcare and be tested, 
and perhaps more likely to test positive.
We are only collecting one sample from each house-
hold member, and not re-sampling the index case, for 
time and resource reasons. This may well lead to missing 
intermittent shedding of oocysts, tertiary household 
infections and/or misclassifying recurring illness.
As Cryptosporidium is common in younger age groups, we 
expect a large proportion of the participants to represent 
families with young children which may lead to over-rep-
resentation of these households. In addition, we might 
expect that having young children who were ill, or being 
severely ill themselves, may incentivise cases to participate 
in the study, more than adult, less severe cases.
Any likely over- or under-representation in the data 
collected will be considered when assessing and describing 
results. Further unidentifiable limitations may include 
Figure 3 Fe-Col kit.
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recall biases around dates of onset or activities, and classi-
fication biases as we are asking about self-reported illness 
and information may be inaccurate.
There is a possibility that we could see ongoing 
outbreaks in the study year. If this happens, we might 
try to identify these where possible and may consider 
excluding households from this study where all or most 
members have been exposed, including a definition of a 
co-primary case.
End of study
The study will be declared as ended when the database is 
closed to recruitment—after 1 year or when the maximum 
number of households has been enrolled.
Pilot arrangements
A pilot phase of 1 month is anticipated before data collec-
tion begins to assess and evaluate processes. Pilot data 
will be included as study data if no major methodological 
changes are proposed.
Ethics and dissemination
The study has been approved by the North West – Liver-
pool East NHS Research Ethics Committee (Reference: 
18/NW/0300) and the Confidentiality and Advisory 
Group (Reference 18/CAG/0084). The project is regis-
tered on the National Institute for Health Research port-
folio (CPMS ID: 39458).
Outputs will include scientific conferences and peer-re-
viewed publications. In addition, a short, lay report of 
findings will be produced for participants, who can opt to 
receive this when they take part.
Author affiliations
1NIHR Health Protection Research Unit in Gastrointestinal Infections, University of 
Liverpool, Liverpool, UK
2NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, 
University of Liverpool, Neston, UK
3Cryptosporidium Reference Unit, Public Health Wales, Swansea, UK
4Swansea University Medical School, Swansea, UK
5Field Epidemiology Services, Health Protection, Public Health England, Liverpool, 
UK
6NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, The 
University of Liverpool, Liverpool, UK
7Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK
8NIHR Clinical Research Network North West Coast, Liverpool, UK
9Department of Epidemiology and Population Health, Institute of Infection and Global 
Health, University of Liverpool, Neston, UK
Acknowledgements John Harris, Goutam Adak, Ken Lamden, Andrew Fox. 
The Clinical Research Network North West Coast, Liverpool. Laura Evans, Public 
Health Wales; Christopher Williams and the Health Protection Team, Public Health 
Wales; Jo Hardstaff, University of Liverpool Richard Dunn and Elaine Mooney, Field 
Services, Public Health England; Infection and Global Heath panel (PPI group) at the 
University of Liverpool, Health and Care Research Wales, and all other public/lay 
contributors to the Public and Patient Involvement survey.
Contributors CMCK, RCha, RV, RChr, SOB conceived the initial idea for the study 
and the methodology. JM contributed to methods for participant recruitment and 
ethics submissions. CMCK wrote the protocol. RChr, RCha, RV, SOB reviewed and 
revised the protocol and the paper. All authors have read and approved the final 
manuscript.
Funding This research is jointly funded by the National Institute for Health 
Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic 
Infections (HPRU EZI) and the National Institute for Health Research Health 
Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections (HPRU GI) at the 
University of Liverpool in partnership with Public Health England (PHE), University of 
East Anglia, University of Oxford and the Institute of Food Research.
disclaimer The views expressed are those of the authors and not necessarily 
those of the NHS, the NIHR, the Department of Health, PHE or Public Health Wales.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study has been approved by the North West – Liverpool East 
NHS Research Ethics Committee (Reference: 18/NW/0300) and the Confidentiality 
and Advisory Group (Reference 18/CAG/0084). 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Chalmers RM, Smith R, Elwin K, et al. Epidemiology of anthroponotic 
and zoonotic human cryptosporidiosis in England and Wales, 2004-
2006. Epidemiol Infect 2011;139:700–12.
 2. Cacciò SM, Putignani L. Epidemiology of Human Cryptosporidiosis. 
In: Cryptosporidium: parasite and disease. Vienna: Springer, 
2014:43–79.
 3. Adak GK, Long SM, O'Brien SJ. Trends in indigenous foodborne 
disease and deaths, England and Wales: 1992 to 2000. Gut 
2002;51:832–41.
 4. Food Standards Agency. A report of infectious intestinal disease in 
England. London, 2000.
 5. Cacciò SM, Thompson RC, McLauchlin J, et al. Unravelling 
Cryptosporidium and Giardia epidemiology. Trends Parasitol 
2005;21:430–7.
 6. Chalmers RM, Giles M. Zoonotic cryptosporidiosis in the UK - 
challenges for control. J Appl Microbiol 2010;109:1487–97.
 7. Hannah J, Riordan T. Case to case spread of cryptosporidiosis; 
evidence from a day nursery outbreak. Public Health 
1988;102:539–44.
 8. Garvey P, McKeown P. Epidemiology of human cryptosporidiosis 
in Ireland, 2004-2006: analysis of national notification data. Euro 
Surveill 2009;14:16–20.
 9. Roy SL, DeLong SM, Stenzel SA, et al. Risk factors for sporadic 
cryptosporidiosis among immunocompetent persons in the United 
States from 1999 to 2001. J Clin Microbiol 2004;42:2944–51.
 10. Hunter PR, Hughes S, Woodhouse S, et al. Sporadic 
cryptosporidiosis case-control study with genotyping. Emerg Infect 
Dis 2004;10:1241–9.
 11. Waldram A, Vivancos R, Hartley C, et al. Prevalence of Giardia 
infection in households of Giardia cases and risk factors for 
household transmission. BMC Infect Dis 2017;17:486.
 12. Minetti C, Lamden K, Durband C, et al. Case-control study of risk 
factors for sporadic giardiasis and parasite assemblages in North 
West England. J Clin Microbiol 2015;53:3133–40.
 13. Davies AP, Campbell B, Evans MR, et al. Asymptomatic carriage 
of protozoan parasites in children in day care centers in the United 
kingdom. Pediatr Infect Dis J 2009;28:838–40.
 14. Johansen ØH, Hanevik K, Thrana F, et al. Symptomatic and 
asymptomatic secondary transmission of Cryptosporidium parvum 
following two related outbreaks in schoolchildren. Epidemiol Infect 
2015;143:1–8.
 15. Hunter PR, Thompson RC. The zoonotic transmission of Giardia and 
Cryptosporidium. Int J Parasitol 2005;35:1181–90.
 16. Frost FJ, Roberts M, Kunde TR, et al. How clean must our drinking 
water be: the importance of protective immunity. J Infect Dis 
2005;191:809–14.
 17. Newman RD, Zu SX, Wuhib T, et al. Household epidemiology 
of Cryptosporidium parvum infection in an urban community in 
northeast Brazil. Ann Intern Med 1994;120:500–5.
 18. Korpe PS, Haque R, Gilchrist C, et al. Natural History of 
Cryptosporidiosis in a Longitudinal Study of Slum-Dwelling 
Bangladeshi Children: Association with Severe Malnutrition. PLoS 
Negl Trop Dis 2016;10:e0004564.
 o
n
 7 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026116 on 21 June 2019. Downloaded from 
9McKerr C, et al. BMJ Open 2019;9:e026116. doi:10.1136/bmjopen-2018-026116
Open access
 19. Korpe PS, Gilchrist C, Burkey C, et al. Case-Control Study of 
Cryptosporidium Transmission in Bangladeshi Households. Clin 
Infect Dis 2018.
 20. ONS. Census - Office for National Statistics. 2011 https://www. ons. 
gov. uk/ peop lepo pula tion andc ommunity/ popu lati onan dmig ration/ 
populationestimates/ bulletins/ popu lati onan dhou seho ldes tima tesf 
orth euni tedk ingdom/ 2011- 03- 21# number- of- people- in- households 
(Accessed 11 Jun 2018).
 21. PHE. Cryptosporidium: national laboratory data - GOV.UK. https://
www. gov. uk/ government/ publications/ cryptosporidium- national- 
laboratory- data (Accessed 11 Jun 2018).
 22. Welsh Government | Census of population. Stat. Res. 2015 https:// 
gov. wales/ statistics- and- research/ census- population/? lang= en 
(accessed 10 Aug 2018.
 23. Wall PG, de Louvois J, Gilbert RJ, et al. Food poisoning: 
notifications, laboratory reports, and outbreaks--where do the 
statistics come from and what do they mean? Commun Dis Rep 
CDR Rev 1996;6:R93–100.
 24. Public Health (Control of Disease) Act 1984. 1984 https://www. 
legislation. gov. uk/ ukpga/ 1984/ 22 (Accessed 10 Aug 2018).
 25. The Health Protection (Notification) Regulations 2010. 2010 http://
www. legislation. gov. uk/ uksi/ 2010/ 659/ regulation/ 4/ made (Accessed 
10 Aug 2018).
 26. Chalmers RM, Atchison C, Barlow K, et al. An audit of the laboratory 
diagnosis of cryptosporidiosis in England and Wales. J Med 
Microbiol 2015;64:688–93.
 27. Public Health England. Cryptosporidium reference unit (CRU) - GOV.
UK. https://www. gov. uk/ guidance/ cryptosporidium- reference- unit- 
cru (Accessed 10 Aug 2018).
 28. Tam CC, Rodrigues LC, Viviani L, et al. Longitudinal study of 
infectious intestinal disease in the UK (IID2 study): incidence in the 
community and presenting to general practice. Gut 2012;61:69–77.
 29. Perry S, de la Luz Sanchez M, Hurst PK, et al. Household 
transmission of gastroenteritis. Emerg Infect Dis 2005;11:1093–6.
 30. Harrison SL, Nelder R, Hayek L, et al. Managing a large outbreak 
of cryptosporidiosis: how to investigate and when to decide to lift a 
‘boil water’ notice. Commun Dis public Heal 2002;5:230–9.
 31. MacKenzie WR, Schell WL, Blair KA, et al. Massive outbreak of 
waterborne cryptosporidium infection in Milwaukee, Wisconsin: 
recurrence of illness and risk of secondary transmission. Clin Infect 
Dis 1995;21:57–62.
 32. Willison DJ, Swinton M, Schwartz L, et al. Alternatives to project-
specific consent for access to personal information for health 
research: insights from a public dialogue. BMC Med Ethics 
2008;9:18.
 33. Taylor MJ, Taylor N. Health research access to personal confidential 
data in England and Wales: assessing any gap in public attitude 
between preferable and acceptable models of consent. Life Sci Soc 
Policy 2014;10:15.
 34. Category B - Medical Packaging, medical pouches and biological 
substances on  un3373. com. http://www. un3373. com/ category- 
biological- substances/ category- b/ (Accessed 10 Aug 2018).
 35. Office for National Statistics. Overview of the Various Geographies 
Used in the Production of Statistics Collected via the UK Census.
 36. Robinson GEK. Methods and Protocols in Cryptosporidium 
Research. Cryptosporidium diagnostic assays: molecular detection. 
In: Mead J, ed. Methods in Molecular Biology: Springer Nature.
 37. Adams NL, Rose TC, Hawker J, et al. Socioeconomic status and 
infectious intestinal disease in the community: a longitudinal study 
(IID2 study). Eur J Public Health 2018;28:134–8.
 38. Public health control and management of hepatitis A 2017 
Guidelines. 2017 https://www. gov. uk/ government/ uploads/ system/ 
uploads/ attachment_ data/ file/ 623036/ Public_ health_ control_ and_ 
management_ of_ hepatitis_ A_ 2017. pdf (Accessed 30 Oct 2017).
 o
n
 7 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026116 on 21 June 2019. Downloaded from 
